• Explore /
  • Poster
  • / Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open-label, single-arm, phase Ib clinical trial.

Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open-label, single-arm, phase Ib clinical trial.

Abstract Poster

Authors

null

Zhigang Liu

Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China

Zhigang Liu , Xiaotao Huang , Jun Liang , Guihua Zhong , Ye Liu , Lizhong Liang , Haiyu Hong , Weineng Feng , Shuang Yang , Yaqin Zhang , Yingpeng Peng , Qiandan Liu , Yuling Zhou , Zhaoyuan Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04947241

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 6023)

DOI

10.1200/JCO.2022.40.16_suppl.6023

Abstract #

6023

Poster Bd #

15

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Genitourinary Cancers Symposium

Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.

Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.

First Author: Xin-Gang Bi

First Author: Xiao Yang

First Author: Matt D. Galsky

First Author: Hailiang Zhang